Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.8200 (11.65%) ($8.0400 - $8.8200) on Wed. Mar. 16, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.63% (three month average) | RSI | 43 | Latest Price | $8.8200(11.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -8.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(69%) ARKK(66%) IBUY(61%) | Factors Impacting TGTX price | TGTX will decline at least -3.815% in a week (0% probabilities). VIXM(-49%) VXX(-42%) UUP(-25%) TBT(-15%) EDOC(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.815% (StdDev 7.63%) | Hourly BBV | 1.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.4(-206.58%) | Resistance Level | $9.4 | 5 Day Moving Average | $8.46(4.26%) | 10 Day Moving Average | $8.65(1.97%) | 20 Day Moving Average | $9.4(-6.17%) | To recent high | -56.8% | To recent low | 13.1% | Market Cap | $1.117b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |